Christopher Riemann, MD
Ophthalmology · Cincinnati, OHNPI 1962491571
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $342,761 of the $462,930 with a category attached, or 74.0%. 36 manufacturers reported payments, led by Haag-streit USA, Inc. at 32.2% of the total. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $962.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$149K
- Medone Surgical Inc$100K
- Astellas Pharma US Inc$52K
- Dutch Ophthalmic Research Center (international) B.v.$37K
- Alcon$23K
- W. L. Gore & Associates, Inc.$20K
- plus $82K from 30 others
Across 41 payments — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$393K
- Ocular Therapeutix, Inc.$77K
- Alimera Sciences, Inc.$47K
- Novartis$40K
- Alcon Research LLC$35K
- ANI Pharmaceuticals, Inc.$23K
What the payments were for
- Royalty or licence$12,8463%
- Consulting fees$342,76174%
- Speaking & faculty fees$71,64515%
- Travel & lodging$17,7894%
- Food & beverage$16,5954%
- Education$1410%
- Gifts$560%
- Entertainment$1,0970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$38,845
- EVA Ophthalmic Surgical System$27,013
- Constellation$22,989
- Product in Development$19,607
- EVA, combined machine$13,525
- TISSUEBLUE$13,525
- Iluvien$12,561
- XIPERE$5,568
- BEOVU$4,575
- NGENUITY$4,556
- CLARUS$4,500
- CIRRUS 6000 with AngioPlex$3,000
- PURIFIED CORTROPHIN GEL$1,889
- ARTEVO 800$1,635
- LOTEMAX SM$1,500
- FORUM$1,500
- OZURDEX$1,300
- EYLEA$1,207
- YUTIQ$492
- VABYSMO$401
How this compares
$462,930 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 375 | $16,440 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $9,980 |
| ProlensaBromfenac Sodium | 12 | $4,194 |
| Difluprednate | 21 | $2,929 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $2,355 |
| Brimonidine Tartrate | 80 | $1,299 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 151 | $1,101 |
| Atropine Sulfate | 22 | $800 |
| Timolol Maleate | 91 | $636 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $422 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $345 |
| Latanoprost | 35 | $335 |
| Diclofenac Sodium | 12 | $171 |
| Ofloxacin | 18 | $161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $3,115 | $9,98035 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,871 | $4,19412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Robert OsherCincinnati$720K
- Anup KhatanaCincinnati$347K
- Michael SnyderCincinnati$216K
- Daniel MillerCincinnati$75K
- Robert SiskCincinnati$46K
- Michael NordlundCincinnati$40K
- Adam KaufmanCincinnati$19K
- Haroon ChaudhryCincinnati$18K
- Karen KlugoCincinnati$17K
- Clara ChanCincinnati$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.